CG MedTech Co

CG MedTech Co Debt/EBITDA

The Total Debt to EBITDA Ratio of CG MedTech Co (056090.KQ) as of Oct 20, 2026 is 0.23. In the previous year, Total Debt to EBITDA Ratio was -4.40 — a change of -105.12% (higher).

Debt/EBITDA

0.23

YoY

-105.12%

Last updated:

Total Debt to EBITDA Ratio of CG MedTech Co is 2025 0.23 . Total Debt to EBITDA Ratio of CG MedTech Co was 2024 -4.40 . It decreases by -105.12% higher compared to the previous year.

The CG MedTech Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-3.34 KRW
Jan 1, 2018
-1.99 KRW
Jan 1, 2019
-44.20 KRW
Jan 1, 2020
-2.34 KRW
Jan 1, 2021
-7.10 KRW
Jan 1, 2022
52.68 KRW
Jan 1, 2024
-4.40 KRW
Jan 1, 2025
0.23 KRW
The CG MedTech Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.23-105.12%
-4.40-108.36%
52.68-841.88%
-7.10+203.48%
-2.34-94.71%
-44.20+2,125.00%
-1.99-40.46%
-3.34+200.37%
-1.11-83.96%
-6.92-175.68%
9.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG MedTech Co Stock analysis

What does CG MedTech Co do? CG MedTech Co Ltd generates revenue through two primary business segments. The Medical Device Business segment produces and sells spinal fixation devices, micro-invasive medical devices for back pain treatment, fracture treatment devices, and bioabsorbable alloy implants. These products are sold to healthcare providers and hospitals within the orthopaedic surgical market. The Electric Energy Business segment manufactures and markets electricity meters and integrated calorimeters, targeting utility companies and energy management sectors. Both segments operate under the company's established brand presence in their respective industries. The company's revenue streams are derived from direct sales to end-users in the medical and energy sectors. Orthopaedic surgical implants and devices are purchased by hospitals and clinics specializing in orthopaedic care, while electricity meters and calorimeters are bought by utility providers for infrastructure deployment. The firm's product portfolio is designed to meet specific technical requirements within these specialized markets. CG MedTech Co Ltd's business model focuses on manufacturing high-precision medical devices and energy measurement equipment. The Medical Device Business segment serves the healthcare industry with products for spinal and fracture treatments, while the Electric Energy Business segment supports energy management through metering solutions. This dual-segment approach allows the company to serve two distinct but complementary industrial sectors. CG MedTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG MedTech Co stock

Total Debt to EBITDA Ratio of CG MedTech Co is 0.23 in 2025.

Total Debt to EBITDA Ratio of CG MedTech Co changed from -4.40 to 0.23, representing a -105.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio CG MedTech Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's CG MedTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CG MedTech Co

All Key Metrics — CG MedTech Co